Last Updated:December 17, 2024, 12:30 IST Not just Tirzepatide, the company plans to launch multiple newly developed products from its global portfolio in the Indian market, including cardiometabolic health, oncology, immunology and neuroscience Mounjaro, a weekly injectable drug by Eli Lilly for treating type 2 diabetes and obesity, competes with another high-profile drug, Ozempic. (Representational pic) Eli Lilly, a US-based pharmaceutical giant, plans to launch its drug, Tirzepatide, sold under the brand name Mounjaro, in the Indian market next year. Mounjaro, a weekly injectable drug by Eli Lilly for treating type 2 diabetes and obesity, competes with another high-profile drug, Ozempic (manufactured by Danish drugmaker, Novo Nordisk). The latter, brand name Ozempic (semaglutide), has not yet been launched in the Indian market. “We aim to launch Tirzepatide in India by 2025, after obtaining all necessary regulatory approvals,” Vineet Gupta, associate vice president and managing director of Eli Lilly (India), told News18. However, he said that the company hasn’t yet “finalised the pricing of Tirzepatide for India”. Gupta did not reveal its pricing strategy for the …